IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors.

CONCLUSIONS: IDH1/2MUT AML cells are sensitive to PARP inhibitors as monotherapy but especially when combined with a DNA-damaging agent such as daunorubicin, whereas concomitant administration of IDH1/2MUT inhibitors during cytotoxic therapy decrease the efficacy of both agents in IDH1/2MUT AML. These results advocate in favor of clinical trials of PARP inhibitors either or not in combination with daunorubicin in IDH1/2MUT AML.
PMID: 29339439 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 16, 2018 Category: Cancer & Oncology Authors: Molenaar RJ, Radivoyevitch T, Nagata Y, Khurshed M, Przychodzen B, Makishima H, Xu M, Bleeker FE, Wilmink JW, Carraway H, Mukherjee S, Sekeres MA, Van Noorden CJF, Maciejewski JP Tags: Clin Cancer Res Source Type: research